Novavax announced that it had earned a $125 million contractual milestone following initiation of Sanofi's Phase III influenza–COVID-19 combination-vaccine trial in Europe.
The milestone was triggered when the fifth participant received treatment in the trial.
The study evaluates the safety and immunogenicity of a combination involving Novavax's Nuvaxovid COVID-19 vaccine and Sanofi's marketed high-dose influenza vaccine in adults aged 60 and older.
Under the collaboration agreement, Novavax remains eligible for a $75 million manufacturing technology-transfer milestone, a potential $225 million milestone following a qualifying U.S. combination-vaccine launch, and future royalties. Novavax Investor Relations
Primary source: Novavax — Official October 29 Announcement
Why it matters strategically
The announcement illustrates a pharmaceutical partnership model in which clinical development and commercialization responsibilities are distributed between companies.
Novavax contributes its vaccine technology.
Sanofi conducts the combination-vaccine development program.
Novavax receives contractual payments linked to specific milestones.
This structure can reduce the need for Novavax to independently finance every stage of development.
However, it also creates dependence on its partner's development priorities, regulatory strategy, and commercial execution.
The $125 million milestone is a confirmed contractual achievement.
It is not evidence that the investigational combination vaccine has demonstrated clinical efficacy or obtained regulatory approval.
